Brief: Rain Therapeutics Initiates Phase 3 Mantra Clinical Trial Of Milademetan For De-Differentiated Liposarcoma And Provides Patient Update From Prior Clinical Program

Rain Oncology

20/07/2021 13:23

July 20 (Reuters) - Rain Therapeutics Inc  RAIN.O :
    * RAIN THERAPEUTICS INITIATES PHASE 3 MANTRA CLINICAL TRIAL
OF
MILADEMETAN FOR DE-DIFFERENTIATED LIPOSARCOMA AND PROVIDES
PATIENT UPDATE FROM PRIOR CLINICAL PROGRAM
    * RAIN THERAPEUTICS INC - AS OF JULY 1, THREE WD/DD LPS
PATIENTS
RECEIVED THERAPY WITH MILADEMETAN MONOTHERAPY FOR GREATER THAN
51 MONTHS
    * RAIN THERAPEUTICS INC - TWO OF THE THREE PATIENTS CONTINUE
TO
RECEIVE THERAPY WITH DURATIONS NOW AT 51 AND 57 MONTHS WITHOUT
DISEASE PROGRESSION
    * RAIN THERAPEUTICS INC - ADDITIONAL PATIENT RECEIVED
THERAPY FOR
GREATER THAN 59 MONTHS BEFORE DISCONTINUATION IN Q2 OF 2021

Source text for Eikon:  ID:nGNX1LKFkl 
Further company coverage:  RAIN.O 

 ((Reuters.Briefs@thomsonreuters.com;))